An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4.

PubWeight™: 0.95‹?› | Rank: Top 15%

🔗 View Article (PMID 7989764)

Published in J Immunol on December 15, 1994

Authors

F Pericle1, M Giovarelli, M P Colombo, G Ferrari, P Musiani, A Modesti, F Cavallo, F Di Pierro, F Novelli, G Forni

Author Affiliations

1: CNR Center for Immunogenetics and Experimental Oncology University of Turin, Italy.

Articles citing this

Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med (1999) 1.82

Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol (1999) 1.47

Eosinophils in innate immunity: an evolving story. Cell Tissue Res (2010) 1.34

Alternative activation of tumor-associated macrophages by IL-4: priming for protumoral functions. Cell Cycle (2010) 1.22

Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. Cancer Res (2007) 1.20

Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest (2003) 1.17

Tumor rejection by modulation of tumor stromal fibroblasts. J Exp Med (2003) 0.91

IL-17-dependent, IFN-gamma-independent tumor rejection is mediated by cytotoxic T lymphocytes and occurs at extraocular sites, but is excluded from the eye. J Immunol (2011) 0.81

Clinical investigation of the role of interleukin-4 and interleukin-13 in the evolution of prostate cancer. Cancers (Basel) (2011) 0.81

Beneficial autoimmunity at body surfaces - immune surveillance and rapid type 2 immunity regulate tissue homeostasis and cancer. Front Immunol (2014) 0.79

Until Death Do Us Part: Necrosis and Oxidation Promote the Tumor Microenvironment. Transfus Med Hemother (2016) 0.78

Proinflammatory and Anti-Inflammatory Cytokines Mediated by NF-κB Factor as Prognostic Markers in Mammary Tumors. Mediators Inflamm (2016) 0.77

Monocyte activation in patients with non-seminomatous germ cell tumour of the testis before and after tumour eradication. J Clin Pathol (1996) 0.77

The tumor protection effect of high-frequency administration of whole tumor cell vaccine and enhanced efficacy by the protein component from Agrocybe aegerita. Int J Clin Exp Med (2015) 0.75

Articles by these authors

A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell (1992) 6.86

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science (1997) 4.58

Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice. EMBO J (1995) 3.48

The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood (2001) 2.92

Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science (1995) 2.79

Transcript imaging of the development of human T helper cells using oligonucleotide arrays. Nat Genet (2000) 2.71

DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol (2000) 2.65

Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential. Gut (2007) 2.49

Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice. EMBO J (2000) 2.41

Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med (1996) 2.32

Antitumor vaccination: where we stand. Haematologica (2000) 2.30

Lifestyle intervention by group care prevents deterioration of Type II diabetes: a 4-year randomized controlled clinical trial. Diabetologia (2002) 2.23

Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med (1991) 2.11

Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med (1998) 2.08

Six-minute walking performance in patients with moderate-to-severe heart failure; is it a useful indicator in clinical practice? Eur Heart J (2001) 2.07

Clinical evaluation of safety and efficacy of Boswellia-based cream for prevention of adjuvant radiotherapy skin damage in mammary carcinoma: a randomized placebo controlled trial. Eur Rev Med Pharmacol Sci (2015) 2.02

Autosomal recessive mitochondrial ataxic syndrome due to mitochondrial polymerase gamma mutations. Neurology (2005) 2.01

Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma. Leukemia (2011) 1.99

Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol (2006) 1.95

T cell assays and MIATA: the essential minimum for maximum impact. Immunity (2012) 1.74

Human monocytes constitutively express membrane-bound, biologically active, and interferon-gamma-upregulated interleukin-15. Blood (1999) 1.71

Myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassaemia major. Heart (2009) 1.71

Reversible immortalization of human myogenic cells by site-specific excision of a retrovirally transferred oncogene. Hum Gene Ther (1999) 1.66

Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med (2001) 1.66

Non-length-dependent small fibre neuropathy. Confocal microscopy study of the corneal innervation. J Neurol Neurosurg Psychiatry (2010) 1.62

Safety of retroviral gene marking with a truncated NGF receptor. Nat Med (2003) 1.60

Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol (1999) 1.60

Partial interferon-gamma receptor signaling chain deficiency in a patient with bacille Calmette-Guérin and Mycobacterium abscessus infection. J Infect Dis (2000) 1.58

Cyclin dependent kinase inhibitors and dominant negative cyclin dependent kinase 4 and 6 promote survival of NGF-deprived sympathetic neurons. J Neurosci (1997) 1.54

Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBO J (1998) 1.50

The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci U S A (1999) 1.47

Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res Hum Retroviruses (2006) 1.47

HOXB7: a key factor for tumor-associated angiogenic switch. Cancer Res (2001) 1.47

Role of STAT3 and PI 3-kinase/Akt in mediating the survival actions of cytokines on sensory neurons. Mol Cell Neurosci (2001) 1.45

Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer. Blood (1994) 1.45

Clonal analysis of stably transduced human epidermal stem cells in culture. Proc Natl Acad Sci U S A (1996) 1.44

Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer (1994) 1.44

Mutations of ANT1, Twinkle, and POLG1 in sporadic progressive external ophthalmoplegia (PEO). Neurology (2003) 1.43

Establishment and characterization of a human neuroblastoma cell line. Int J Cancer (1989) 1.43

High efficiency myogenic conversion of human fibroblasts by adenoviral vector-mediated MyoD gene transfer. An alternative strategy for ex vivo gene therapy of primary myopathies. J Clin Invest (1998) 1.43

Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma. J Exp Med (1993) 1.43

An international comparison of knowledge levels of medical students: the Maastricht Progress Test. Med Educ (1996) 1.42

Concomitant factors of decompensation in chronic heart failure. Am J Cardiol (1996) 1.42

Interferon-gamma receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death. J Leukoc Biol (2001) 1.39

Incidence and prevalence rate estimation of GH treatment exposure in Piedmont pediatric population in the years 2002-2004: Data from the GH Registry. J Endocrinol Invest (2006) 1.39

Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res (1992) 1.39

Regulation of base balance in bicarbonate hemofiltration. Int J Artif Organs (1994) 1.38

Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. Lab Invest (1999) 1.37

Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells. Cancer Immunol Immunother (2009) 1.36

Group B streptococci persist inside macrophages. Immunology (1998) 1.36

CD8+ T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression. Proc Natl Acad Sci U S A (2000) 1.35

HOXB7 constitutively activates basic fibroblast growth factor in melanomas. Mol Cell Biol (1996) 1.35

Expression of transcripts for two interleukin 8 receptors in human phagocytes, lymphocytes and melanoma cells. Biochem J (1993) 1.32

Constitutive expression of lymphoma-associated NFKB-2/Lyt-10 proteins is tumorigenic in murine fibroblasts. Oncogene (1997) 1.31

Inhibition of interferon-gamma may suppress allograft reactivity by T lymphocytes in vitro and in vivo. Science (1985) 1.30

Distribution of interferon-gamma receptor in human tissues. Eur J Immunol (1992) 1.30

Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst (1997) 1.30

Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today (1994) 1.29

The role of the macrophage as the stimulator cell in contact sensitivity. J Immunol (1977) 1.28

Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. Am J Pathol (1997) 1.28

Formation of a matter-wave bright soliton. Science (2002) 1.27

Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response. Proc Natl Acad Sci U S A (1999) 1.27

Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab (2007) 1.26

Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J Exp Med (1999) 1.26

The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor. Blood (1999) 1.25

Stimulation of 45Ca efflux from smooth muscle cells by metabolic inhibition and high K depolarization. Pflugers Arch (1975) 1.24

Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J Immunol (1995) 1.23

Mental, physical and functional status in primary care attenders. Int J Psychiatry Med (1999) 1.21

Cystine accumulation and clearance by normal and cystinotic leukocytes exposed to cystine dimethyl ester. Proc Natl Acad Sci U S A (1982) 1.21